|
시장보고서
상품코드
2088723
합성생물학 시장 : 제품 유형, 기술, 분자 유형, 용도, 최종 사용자별 예측(2026-2032년)Synthetic Biology Market by Product Type, Technology, Molecule Type, Application, End User - Global Forecast 2026-2032 |
||||||
360iResearch
합성생물학 시장은 2032년까지 연평균 복합 성장률(CAGR) 9.73%로 338억 9,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 176억 9,000만 달러 |
| 추정 연도 : 2026년 | 193억 8,000만 달러 |
| 예측 연도 : 2032년 | 338억 9,000만 달러 |
| CAGR(%) | 9.73% |
합성생물학 시장 개요
합성생물학은 연구 주도형 분야에서 헬스케어, 농업, 화학, 소재, 식품 시스템 및 환경 분야로의 응용을 목표로 하는 산업 플랫폼으로 전환되고 있습니다. DNA 합성, 유전체 편집, 고처리량 스크리닝, 자동화 및 클라우드 기반 바이오파운드리 분야의 발전 덕분에, 연구 기관들은 생물학적 시스템을 더 신속하고, 더 정확하게, 그리고 재현성 있게 설계할 수 있게 되었습니다.
합성생물학 분야의 획기적인 변화
합성생물학 분야는 생물학, 공학, 계산과학, 그리고 첨단 제조 기술의 융합을 통해 재구성되고 있습니다. 바이오파운드리(Biofoundry)는 '설계·구축·시험·학습'의 주기를 표준화하고 있으며, 한편 자동 액체 핸들링, 오믹스 분석, 차세대 염기서열 분석, 실험실용 로봇 기술은 처리 능력과 데이터 품질의 향상에 기여하고 있습니다.
인공지능의 누적 영향
인공지능은 단백질 설계, 대사 경로 공학, 균주 최적화, 생물학적 데이터 분석, 실험 계획 개선을 통해 합성 생물학의 핵심 원동력이 되어가고 있습니다. AI 모델은 실용 가능한 유전자 구축체, 효소, 대사 경로 및 치료 후보 물질을 규명하는 데 필요한 실험실 내 반복 횟수를 줄이는 데 기여하고 있습니다.
주요 지역별 인사이트: 전 세계 합성생물학 수요
중국, 인도, 일본, 한국, 싱가포르, 호주가 유전체학, 바이오 제조, 바이오 경제와 관련된 프로그램을 확대함에 따라, 아시아태평양은 합성생물학 활동이 활발한 지역으로 자리매김하고 있습니다. 중국은 유전체 분석, 세포 치료 연구, 산업용 생명공학 및 바이오 제조 인프라에 막대한 투자를 하고 있는 반면, 인도는 정부 주도의 바이오경제 이니셔티브, 백신 생산, 바이오시밀러, 농업 생명공학을 통해 생명공학 역량을 구축하고 있습니다. 일본, 한국, 싱가포르, 호주는 정밀의료, 발효, 첨단 소재, 바이오 파운드리 인프라 및 산업용 생명공학 분야에서 강력한 역량을 발휘하고 있습니다.
주요 그룹에 대한 인사이트: 아세안(ASEAN), GCC, EU, 브릭스(BRICS), G7, 나토(NATO)
싱가포르, 말레이시아, 태국, 인도네시아, 베트남, 필리핀이 생의학 연구, 정밀의료, 식품 기술, 바이오 제조에 투자하고 있어 아세안(ASEAN)의 중요성이 커지고 있습니다. 싱가포르는 유기적으로 연계된 연구 인프라, 첨단 바이오 제조 역량, 지원적인 공공 자금, 그리고 강력한 제약·생명과학 생태계를 바탕으로 이 지역에서 가장 강력한 합성생물학 거점으로 자리매김하고 있습니다. 한편, 태국과 말레이시아는 농업, 발효, 재생 가능한 생물 유래 원료와 관련된 바이오경제 프로그램을 강화하고 있습니다.
주요 국가의 동향 : 합성생물학의 주요 시장
미국은 벤처 자금, 첨단 치료법, 클라우드 랩, 유전체 공학, 바이오 파운드리 인프라를 통해 합성생물학의 상용화를 주도하고 있습니다. 한편, 캐나다는 유전체학, 백신, 정밀의료, 지속 가능한 바이오프로세스 분야에서 강점을 보이고 있습니다. 멕시코는 바이오 제조, 의료기기, 농업 생명공학 분야에서 기회를 창출하고 있으며, 브라질은 바이오연료, 사탕수수를 기반으로 한 생명공학, 열대 농업, 바이오 산업용 원료 분야에서 확고한 입지를 다지고 있습니다.
업계 리더를 위한 실천적인 제안
업계의 리더는 단일 자산 개발보다 플랫폼 전략을 우선시해야 합니다. AI 설계 도구, 자동화, 고품질의 생물학적 데이터 세트, 실험실 정보 시스템, 그리고 확장 가능한 발효 및 세포 처리 능력을 통합한 조직은 개발 기간 단축, 재현성 향상, 기술 이전 강화 측면에서 더 유리한 입지를 확보할 수 있습니다.
조사 방법
본 요약본은 정부의 바이오경제 전략, 유전체 시퀀싱 비용 데이터, 규제 당국의 승인, 동료 심사를 거친 생명공학 문헌, 특허 및 정책 관련 간행물, 임상 및 농업 생명공학의 최신 동향, 그리고 공개된 업계 정보 등, 과학, 규제, 기관의 공개 정보원을 바탕으로 한 2차 조사에 근거하고 있습니다. 본 분석에서는 합성생물학, 유전체 공학, AI를 활용한 신약 개발, 바이오 제조, 바이오 보안, 그리고 지역 혁신 시스템에 걸쳐 있는 검증 가능한 동향에 중점을 두고 있습니다.
결론: 전략적 전망
합성생물학은 생명공학 주도의 성장의 다음 단계에서 기반 기술이 되어가고 있습니다. 그 가치는 첨단 치료법, 진단법, 백신, 생물학적 제제부터 지속 가능한 화학 물질, 식품 원료, 농업 자재, 바이오센서, 기후 변화와 관련된 소재에 이르기까지, 특정 성과를 얻기 위해 생물 시스템을 설계하는 능력에 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향, 2026년
제7장 합성생물학 시장 : 제품 유형별
제8장 합성생물학 시장 : 기술별
제9장 합성생물학 시장 : 분자 유형별
제10장 합성생물학 시장 : 용도별
제11장 합성생물학 시장 : 최종 사용자별
제12장 합성생물학 시장 : 지역별
제13장 합성생물학 시장 : 그룹별
제14장 합성생물학 시장 : 국가별
제15장 경쟁 구도
제16장 기업 개요
JHS 26.07.22The Synthetic Biology Market is projected to grow by USD 33.89 billion at a CAGR of 9.73% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 17.69 billion |
| Estimated Year [2026] | USD 19.38 billion |
| Forecast Year [2032] | USD 33.89 billion |
| CAGR (%) | 9.73% |
Synthetic Biology Market Introduction
Synthetic biology is moving from a research-driven discipline into an industrial platform for healthcare, agriculture, chemicals, materials, food systems, and environmental applications. Advances in DNA synthesis, genome editing, high-throughput screening, automation, and cloud-enabled biofoundries are enabling organizations to design biological systems with greater speed, precision, and reproducibility.
The sector is supported by measurable technology progress. The U.S. National Human Genome Research Institute has documented a steep decline in genome sequencing costs from approximately USD 100 million per genome in 2001 to near the USD 1,000 level in recent years. This cost compression, combined with CRISPR-based editing, mRNA platforms, and AI-assisted biological design, is expanding the commercial feasibility of engineered cells, enzymes, microbes, biosensors, and nucleic acid-based products.
Transformative Shifts in the Synthetic Biology Landscape
The synthetic biology landscape is being reshaped by the convergence of biology, engineering, computation, and advanced manufacturing. Biofoundries are standardizing the design-build-test-learn cycle, while automated liquid handling, omics analytics, next-generation sequencing, and laboratory robotics are improving throughput and data quality.
Commercial demand is shifting from isolated proof-of-concept projects toward scalable platforms. Pharmaceutical developers are using synthetic biology for cell and gene therapies, mRNA technologies, biologics optimization, and programmable medicines. Industrial biotechnology is deploying engineered microbes to produce specialty chemicals, enzymes, biomaterials, and alternative proteins, while agricultural applications focus on biological inputs, nitrogen-use efficiency, crop resilience, and reduced dependence on synthetic chemical inputs.
Cumulative Impact of Artificial Intelligence
Artificial intelligence is becoming a core accelerator for synthetic biology by improving protein design, pathway engineering, strain optimization, biological data interpretation, and experimental planning. AI models help reduce the number of wet-lab iterations required to identify viable genetic constructs, enzymes, metabolic pathways, and therapeutic candidates.
The impact is cumulative because each experimental cycle generates structured biological data that can improve future model performance. AI-enabled protein structure prediction, generative sequence design, automated literature mining, and robotic experimentation are strengthening the connection between computational prediction and biological validation, supporting faster product development in therapeutics, enzymes, diagnostics, bio-based chemicals, sustainable materials, and precision agriculture.
Key Regional Insights: Global Synthetic Biology Demand
Asia-Pacific is becoming a high-activity synthetic biology region as China, India, Japan, South Korea, Singapore, and Australia expand genomics, biomanufacturing, and bioeconomy programs. China has invested heavily in sequencing, cell therapy research, industrial biotechnology, and biomanufacturing infrastructure, while India is building biotechnology capacity through government-backed bioeconomy initiatives, vaccine production, biosimilars, and agricultural biotechnology. Japan, South Korea, Singapore, and Australia contribute strong capabilities in precision medicine, fermentation, advanced materials, biofoundry infrastructure, and industrial biotechnology.
North America remains a global leader, driven by the United States and Canada. The United States benefits from deep venture capital, NIH and NSF-funded research, advanced therapy regulatory pathways, academic translation, and federal bioeconomy policy support, while Canada contributes strengths in genomics, vaccines, precision medicine, and sustainable biomanufacturing. Europe is anchored by the European Union, Germany, France, the United Kingdom, Italy, and Spain, with strong academic translation, industrial biotechnology clusters, and sustainability-oriented regulation. Latin America, led by Brazil and Mexico, is advancing bio-based agriculture, biofuels, and industrial fermentation, while the Middle East is increasing biotechnology investment through food security, healthcare modernization, and GCC-led diversification strategies. Africa is emerging through genomics initiatives, infectious disease surveillance, agricultural biotechnology, and capacity-building programs that support local bioeconomy development.
Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO
ASEAN is gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines invest in biomedical research, precision health, food technology, and bio-based manufacturing. Singapore is the region's strongest synthetic biology hub due to coordinated research infrastructure, advanced biomanufacturing capability, supportive public funding, and a strong pharmaceutical and life sciences ecosystem, while Thailand and Malaysia are strengthening bioeconomy programs linked to agriculture, fermentation, and renewable biological feedstocks.
The GCC is using biotechnology to support economic diversification, healthcare security, and food resilience, with Saudi Arabia, the United Arab Emirates, and Qatar funding life sciences ecosystems, genomics programs, and controlled-environment agriculture. The European Union emphasizes safe, sustainable, and regulated biotechnology through research funding, biosafety governance, circular bioeconomy priorities, and programs such as Horizon Europe. BRICS economies bring scale in population health, agriculture, manufacturing, and feedstock availability, while G7 countries dominate advanced R&D, regulatory capacity, intellectual property development, and commercialization pathways. NATO members are also increasing attention to biosecurity, supply-chain resilience, dual-use governance, and the protection of critical biotechnology infrastructure.
Key Country Insights: Leading Synthetic Biology Markets
The United States leads synthetic biology commercialization through venture funding, advanced therapeutics, cloud labs, genome engineering, and biofoundry infrastructure, while Canada contributes strengths in genomics, vaccines, precision medicine, and sustainable bioprocessing. Mexico is building opportunity in biomanufacturing, medical devices, and agricultural biotechnology, and Brazil has a strong position in biofuels, sugarcane-based biotechnology, tropical agriculture, and bio-based industrial inputs.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine world-class research with industrial biotechnology demand, advanced manufacturing, clinical translation, and sustainability-driven policy support, while Russia maintains capabilities in life sciences, agriculture, vaccine research, and biosecurity-related research. China is scaling genomics, cell therapy, fermentation, and biomanufacturing; India is expanding vaccines, biosimilars, diagnostics, and bio-based agriculture; Japan and South Korea are strong in precision medicine, biologics, automation, and industrial fermentation; and Australia is advancing synthetic biology for health, agriculture, mining, environmental resilience, and biosecurity preparedness.
Actionable Recommendations for Industry Leaders
Industry leaders should prioritize platform strategies rather than single-asset development. Organizations that integrate AI design tools, automation, high-quality biological datasets, laboratory information systems, and scalable fermentation or cell-processing capacity are better positioned to reduce development timelines, improve reproducibility, and strengthen technology transfer.
Executives should also strengthen regulatory engagement, biosafety systems, biosecurity controls, and intellectual property strategy early in the development cycle. Partnerships with universities, public biofoundries, contract development and manufacturing organizations, and cloud-lab providers can accelerate validation. Leaders should map feedstock availability, supply-chain risks, energy requirements, workforce capabilities, and regional incentives before scaling commercial biomanufacturing assets.
Research Methodology
This executive summary is based on secondary research from public scientific, regulatory, and institutional sources, including government bioeconomy strategies, genome sequencing cost data, regulatory approvals, peer-reviewed biotechnology literature, patent and policy publications, clinical and agricultural biotechnology updates, and publicly available industry disclosures. The analysis emphasizes verifiable trends across synthetic biology, genome engineering, AI-enabled discovery, biomanufacturing, biosecurity, and regional innovation systems.
Insights were synthesized using a triangulation approach that compares technology adoption, policy direction, funding priorities, regulatory developments, scientific publication trends, infrastructure maturity, and commercial use cases. Geographic analysis considers research infrastructure, manufacturing capability, healthcare demand, agricultural priorities, feedstock access, workforce readiness, and biosecurity governance to identify practical opportunities and constraints across major markets.
Conclusion: Strategic Outlook
Synthetic biology is becoming a foundational technology for the next phase of biotechnology-led growth. Its value lies in the ability to engineer biological systems for targeted outcomes, from advanced therapies, diagnostics, vaccines, and biologics to sustainable chemicals, food ingredients, agricultural inputs, biosensors, and climate-relevant materials.
The strongest opportunities will emerge where AI, automation, regulatory readiness, biosafety governance, and scalable biomanufacturing converge. Organizations that invest in trusted data, responsible innovation, resilient supply chains, and regional partnerships will be best positioned to capture long-term value in the global synthetic biology market.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Synthetic Biology Market, by Product Type
- 7.1. Enzymes
- 7.1.1. DNA Modifying Enzymes
- 7.1.1.1. Restriction Enzymes
- 7.1.1.2. Polymerases
- 7.1.1.3. Ligases
- 7.1.2. RNA Modifying Enzymes
- 7.1.2.1. Reverse Transcriptases
- 7.1.2.2. RNA Polymerases
- 7.1.3. Protein Engineering Enzymes
- 7.1.3.1. Proteases
- 7.1.3.2. Chaperones
- 7.1.1. DNA Modifying Enzymes
- 7.2. Oligonucleotides
- 7.3. Genetic Material
- 7.4. Kits & Reagents
- 7.4.1. Cloning Kits
- 7.4.2. PCR Kits
- 7.4.3. Genome Editing Kits
- 7.5. Software
- 7.5.1. Design Software
- 7.5.2. Simulation Software
- 7.5.3. Analysis Software
- 7.6. Services
- 7.6.1. Gene Synthesis Services
- 7.6.2. DNA Assembly Services
- 7.6.3. Protein Expression Services
8. Synthetic Biology Market, by Technology
- 8.1. Genome Editing
- 8.1.1. CRISPR Cas Systems
- 8.1.2. TALENs
- 8.2. DNA Synthesis
- 8.2.1. Chemical Synthesis
- 8.2.2. Enzymatic Synthesis
- 8.3. Gene Assembly
- 8.4. Metabolic Engineering
- 8.5. Synthetic Genomics
- 8.6. Cell Free Systems
9. Synthetic Biology Market, by Molecule Type
- 9.1. DNA Based Systems
- 9.2. RNA Based Systems
- 9.3. Protein Based Systems
- 9.4. Metabolic Pathway Systems
10. Synthetic Biology Market, by Application
- 10.1. Agriculture
- 10.1.1. Genetically Modified Crops
- 10.1.2. Synthetic Fertilizers
- 10.2. Environmental
- 10.2.1. Bioremediation
- 10.2.2. Carbon Capture
- 10.2.3. Waste Treatment
- 10.3. Industrial
- 10.3.1. Biocatalysts
- 10.3.2. Biofuels
- 10.3.3. Bioplastics & Biopolymers
- 10.3.4. Specialty Chemicals
- 10.4. Life Sciences
- 10.4.1. Drug Discovery
- 10.4.2. Gene Therapy
- 10.4.3. Personalized Medicine
- 10.4.4. Vaccine Development
11. Synthetic Biology Market, by End User
- 11.1. Academic & Research Institutes
- 11.2. Agriculture & Food Companies
- 11.3. Contract Research Organizations
- 11.4. Pharmaceutical & Biotechnology Companies
12. Synthetic Biology Market, by Region
- 12.1. Asia-Pacific
- 12.2. North America
- 12.3. Latin America
- 12.4. Europe
- 12.5. Middle East
- 12.6. Africa
13. Synthetic Biology Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
14. Synthetic Biology Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
15. Competitive Landscape
- 15.1. Market Concentration Analysis, 2025
- 15.1.1. Concentration Ratio (CR)
- 15.1.2. Herfindahl Hirschman Index (HHI)
- 15.2. Recent Developments & Impact Analysis, 2025
- 15.3. Product Portfolio Analysis, 2025
- 15.4. Benchmarking Analysis, 2025
16. Company Profiles
- 16.1. Agilent Technologies, Inc.
- 16.2. Amyris, Inc.
- 16.3. Arzeda
- 16.4. Batavia Biosciences B.V.
- 16.5. Beam Therapeutics
- 16.6. BGI Genomics Co., Ltd.
- 16.7. Codexis, Inc.
- 16.8. Conagen, Inc.
- 16.9. Creative Enzymes
- 16.10. Danaher Corporation
- 16.11. DNA TwoPointO Inc.
- 16.12. Editas Medicine, Inc.
- 16.13. Eurofins Scientific SE
- 16.14. GenScript Biotech Corporation
- 16.15. Ginkgo Bioworks, Inc.
- 16.16. Illumina, Inc.
- 16.17. Merck KGaA
- 16.18. New England Biolabs GmbH
- 16.19. Novozymes A/S
- 16.20. Precigen, Inc.
- 16.21. QIAGEN N.V.
- 16.22. Sangamo Therapeutics
- 16.23. Scarab Genomics, LLC
- 16.24. Synlogic
- 16.25. Synthego Corporation
- 16.26. TeselaGen Service
- 16.27. Thermo Fisher Scientific Inc.
- 16.28. Twist Bioscience Corporation
